Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETHOS: PT010 vs PT003 and PT009 in COPD
NCT02465567Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Jun 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics. Primary endpoint: Adjusted Rate of Moderate or Severe Exacerbations at 52 weeks. Started Jun 2015; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02465567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465567.